Increased PD‐L1 mRNA levels in the GR group correlated with BRCA2 mutation status (p = 0.013) but not with BRCA1 mutations (Figure 4A) and PD‐L1 protein expression in tumor immune cells was significantly higher in those patients with mutations in BRCA2 (p = 0.029) (Figure 4B). Here, BRCA2 is linked to neoplasm.